What is the long-term trend for Boston Scientific's debt instrument, fair value disclosure?

Over 5 years (2020 to 2025), Boston Scientific's debt instrument, fair value disclosure has grown at a 0.7% compound annual growth rate (CAGR), from $10.77B to $11.15B.

Boston Scientific BSX Debt Instrument, Fair Value Disclosure

Debt Instrument, Fair Value Disclosure at other companies

Arch Capital GroupACGL

$566.2M+2.5%

Bank of AmericaBAC

$820B-2.7%

LennarLEN

$4.11B+85.3%

Chicago Atlantic Real Estate FinanceREFI

$29.25M—

EFC

Ellington Financial Inc.EFC

$3.13B+62.2%

NRZ

New Residential Investment Corp.NRZ

——

Other financials

Income statement

See full

Revenue$5.2B+11.6%

Gross profit$3.6B+12.6%

Operating income$1.1B+19.5%

Net income$1.3B+99.3%

EPS (diluted)$0.90+100%

Balance sheet

See full

Cash & equivalents$850.0M+146%

Total equity$25.9B+16.4%

Total assets$44.4B+10.5%

Cash flow

See full

Operating cash flow$348.0M-35.7%

CapEx$177.0M-5.4%

Free cash flow$171.0M-51.7%

Valuation

See full

Market cap$67.32B-37.5%

P/E18.9×-34.3×

P/S3.3×-2.9×

Profitability

See full

Gross margin69.2%+0.5pp

Operating margin18.4%+2.2pp

Net margin17.3%+5.7pp

Returns & leverage

See full

Return on equity14.8%+5.2pp

Debt / equity0×-0.5×

Current ratio1.9×+0.4×

Where this comes from

Reported directly by Boston Scientific in its filing.

Tagged under the XBRL concept us-gaap:DebtInstrumentFairValue.

The official record: Boston Scientific’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Boston Scientific's debt instrument, fair value disclosure.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Boston Scientific's debt instrument, fair value disclosure?: Boston Scientific (BSX) reported debt instrument, fair value disclosure of $10.59B in Q1 2026.
How has Boston Scientific's debt instrument, fair value disclosure changed year-over-year?: Boston Scientific's debt instrument, fair value disclosure decreased by 2.9% year-over-year, from $10.9B to $10.59B.
What is the long-term trend for Boston Scientific's debt instrument, fair value disclosure?: Over 5 years (2020 to 2025), Boston Scientific's debt instrument, fair value disclosure has grown at a 0.7% compound annual growth rate (CAGR), from $10.77B to $11.15B.